PATENT CLAIM ANALYSIS

Application Number: 15885147
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "419000"]

Abstract:
The disclosure provides methods of treating a condition, disease, or disorder in a subject that involves metabolically reprogrammed cells whose activation, function, growth, proliferation, or survival depends on increased activity of at least one metabolic pathway selected from the group consisting of glutamine metabolism, glycolysis, and fatty acid synthesis, comprising administering to the subject a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 2 ′, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Claim (Index 9):
The method of  claim 8 , wherein:\n R 1  is C 1-4  alkyl; R 11  is selected from the group consisting of isopropyl, sec-butyl, CH 2 CH(CH 3 ) 2 , and CH 2 -3-indoyl; R 12  is selected from the group consisting of H and \u2014C(\u2550O)R 13 ; and R 13  is C 1-4  alkyl.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.5125
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15885258', '15263033', '15612877', '15502105', '15314959']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7971094768616569
- 35 USC 102 Novelty (BERT): 0.5196388728929073
- Combined Prediction Score: 0.7693624164647819
- Mean Citation Score: 261.962262
- Max Citation Score: 302.14194
- Similarity Product: 185.3949114177203

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test